Association between the Epidermal Growth Factor 61*A/G Polymorphism and Hepatocellular Carcinoma Risk: a Meta-Analysis

  • Sun, Shuang (Department of Laboratory Medicine, The First Affiliated Hospital of China Medical University) ;
  • Jin, Guo-Jiang (Department of Laboratory Medicine, The First Affiliated Hospital of China Medical University) ;
  • Zhao, Yan (Liaoning Center for Disease Control and Prevention) ;
  • Kang, Hui (Department of Laboratory Medicine, The First Affiliated Hospital of China Medical University)
  • Published : 2015.04.14


The epidermal growth factor (EGF) may play a pathological role in hepatocellular carcinoma (HCC). However, the conclusions of published reports on the relationship between the EGF $61^*A/G$ polymorphism and HCC risk remain controversial. To derive a more precise estimation we performed a meta-analysis based on 14 studies that together included 2,506 cases and 4,386 controls. PubMed, EMBASE, Web of Knowledge and the Chinese National Knowledge Infrastructure (CNKI) databases were used to retrieve articles up to August 1, 2014. The crude odds ratios (ORs) with 95% confidence intervals (95%CIs) were calculated to evaluate the association. Meta-analysis results showed a significant association between the EGF $61^*A/G$ polymorphism and HCC risk in all four genetic models (allele model: OR=1.25, 95%CI=1.12-1.40; dominant model: OR=1.32, 95%CI=1.14-1.54; recessive model: OR=1.33, 95%CI=1.12-1.58; ho-mozygous model: OR=1.59, 95%CI=1.33-1.90). Moreover, significant associations were observed when stratified by ethnicity, source of controls, etiology and genotype methods. Thus, this meta-analysis suggests that the G-allele of the EGF $61^*A/G$ polymorphism is associated with an increased risk of HCC, especially in Asians and Caucasians, without influence from the source of controls or etiological diversity. Further studies with larger population sizes are needed to confirm these results.


Hepatocellular carcinoma;polymorphism;meta-analysis;EGF $61^*A/G$


  1. Abbas E, Shaker O, Abd El Aziz G, et al (2012). Epidermal growth factor gene pol-ymorphism 61A/G in patients with chronic liver disease for early detection of hepa-tocellular carcinoma: a pilot study. Eur J Gastroenterol Hepatol, 24, 458-63.
  2. Abu Dayyeh BK, Yang M, Fuchs BC, et al (2011). a functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology, 141, 141-9.
  3. Blanc P, Etienne H, Daujat M, et al (1992). Mitotic responsiveness of cultured adult human hepatocytes to epidermal growth factor, transforming growth factor alpha, and human serum. Gastroenterology, 102, 1340-50.
  4. Chen K, Wei Y, Yang H, et al (2011). Epidermal growth factor +61 G/A polymor-phism and the risk of hepatocellular carcinoma in a chinese population. Genet Test Mol Biomarkers, 15, 251-5.
  5. Chuang SC, La Vecchia C, Boffetta P (2009). Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett, 286, 9-14.
  6. Chung YH, Kim JA, Song BC, et al (2002). Expression oftransforming growth fac-tor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer, 89, 977-82.
  7. DerSimonian R, Laird NM (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  8. El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and mo-lecular carcinogenesis. Gastroenterology, 132, 2557-76.
  9. El-Serag HB (2011). Hepatocellular carcinoma. New Engl J Med, 365, 1118-27.
  10. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a metaanalysis. Statistics Medicine, 21, 1539-58.
  11. Jorissen RN, Walker F, Pouliot N, et al (2003). Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res, 284, 31-53.
  12. Lanuti, M (2008). A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res, 14, 3216-22.
  13. Li Y, Xie Q, Lu F, et al (2010). Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver Int, 30, 112-8.
  14. Llovet JM, Bruix J (2008). Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 48, 1312-27.
  15. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retro-spective studies of disease. J Natl Cancer Inst, 22, 719-48.
  16. Natarajan A, Wagner B, Sibilia M (2007). The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci USA, 104, 17081-6.
  17. Nicholas MK, Lukas RV, Jafri NF, et al (2006). Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res, 12, 7261-70.
  18. Qi P, Chen YM, Gao CF, et al (2008). Relationship between polymorphism of epi-dermal growth factor 59UTR Variant G61A gene and hepatocellular carcinoma in pa-tients with chronic hepatitis B virus infection in China. Chin J Biologicals, 21, 1051-3.
  19. Qi P, Wang H, Chen YM, et al (2009). No association of EGF 5'UTR variant A61G and hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. Pathology, 41, 555-60.
  20. Shahbazi M, Pravica V, Nasreen N, et al (2002). Association between functional polymorphism in EGF gene and malignant melanoma. Lancet, 359, 397-401.
  21. Shi HZ, Ren P, Lu QJ, et al (2012). Association between EGF, TGF-${\beta}1$ and TNF-$\alpha$ gene polymorphisms and hepatocellular carcinoma. Asian Pac J Cancer Prev, 13, 6217-20.
  22. Stoscheck CM, King LE Jr (1986). Role of epidermal growth factor in carcinogenesis. Cancer Res, 46, 1030-7.
  23. Suenaga M, Yamada S, Fujii T, et al (2013). afunctional polymorphism in the epi-dermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis cpatients. Onco Targets Ther, 6, 1805-12.
  24. Tanabe KK, Lemoine A, Finkelstein DM, et al (2008). Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA, 299, 53-60.
  25. Wang HX, Xie WM, Zhou GQ (2009). Epidermal growth factor gene polymorphism associated with susceptibility to hepatocellular carcinoma. Guangxi Medical Univer-sity. Master Dissertation.
  26. Wu J, Zhang W, Xu A, et al (2013). Association of epidermal growth factor and epidermal growth factor receptor polymorphisms with the risk of hepatitis b vi-rus-related hepatocellular carcinoma in the population of north china. Genet Test Mol Biomarkers, 17, 595-600.
  27. Yamaguchi K, Carr BI, Nalesnik MA (1995). Epidermal growth factor-induced hepa-tocellular carcinoma: gene expression profiles in precursor lesions, early stage and sol-itary tumours. J Surg Oncol, 58, 240-5.
  28. Yang Z, Wu Q, Shi Y, et al (2012). Epidermal growth factor 61A>G polymorphism is associated with risk of hepatocellular carcinoma: a meta-analysis. Genet Test Mol Biomarkers, 16, 1086-91.
  29. Yuan JM, Fan Y, Ognjanovic S, et al (2013). Genetic polymorphisms of epidermal growth factor in relation to risk of hepatocellular carcinoma: two case-control studies. BMC Gastroenterol, 18, 13, 32.
  30. Yue AM, Xie ZB, Guo SP, et al (2013). Implication of polymorphisms in DNA repair genes in prognosis of hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 355-8.
  31. Zender L, Villanueva A, Tovar V, et al (2010). Cancer gene discovery in hepatocellu-lar carcinoma. J Hepatol, 52, 921-9.
  32. Zintzaras E, Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genetic epidemiology, 28, 123-37.
  33. Zhong JH, You XM, Gong WF, et al (2012). Epidermal growth factor gene poly-morphism and risk of hepatocellular carcinoma: a meta-analysis. PLoS One, 7, 32159.

Cited by

  1. EGF+61 A>G polymorphism is not associated with lung cancer risk in the Brazilian population pp.1573-4978, 2019,